Share Name Share Symbol Market Type Share ISIN Share Description
Ixico Plc LSE:IXI London Ordinary Share GB00BFXR4C20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -1.23% 80.50 79.00 82.00 81.50 80.50 81.50 8,265 09:30:34
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 9.5 0.9 2.0 39.9 39

Ixico Share Discussion Threads

Showing 576 to 596 of 600 messages
Chat Pages: 24  23  22  21  20  19  18  17  16  15  14  13  Older
Blogpost update at michae1mouse.blogspot.com
Ixico seeing success with a number of contracts awarded covering multiple therapeutic indications. https://www.youtube.com/c/Proactive247/videos Well worth watching
hTTps://www.londonstockexchange.com/news-article/IXI/new-contract-worth-750k/15143906 The second contract award announced by IXICO this week, and a very significant one. The contract is worth >£750k, but more importantly it's the first contract award from new Imaging Master Vendor Agreement with top 5 global CRO and is expected to significantly enhance IXICO's opportunity to partner with the CRO's client portfolio.
Thanks Toffeeman, it must be an "age thing" as I didn't see the dash after Sphere.
>> bienny2 it was to answer a post which was wondering if the contract was new and it wasn't. See above
Toffeeman - what is that in relation to?
>> Sphere - contract was in Dec 2020 so v old story
Is anticipating "returning to a double-digit revenue growth trajectory as their 2022 financial year progresses" the same thing as forecasting that FY22 revenues will be 10% or more than FY21 revenues? It sounds slightly more woolly and maybe only that the revenue pick up happens at the back end of FY22? I see the Cenkos note also uses a slightly ambiguous phrase that revenue growth should return to double digits "during FY22E". Also I was surprised that Cenkos's note included no actual numerical forecasts for FY21 nor FY22E - just a restatement of the historical accounts upto FY20.
jane deer
Solid update for trading year ending Sept '21 with revenues at £8.7m and EBTIDA of £1.2m. Most importantly they anticipate returning to a double-digit revenue growth trajectory as their 2022 financial year progresses. Remains on track. Excellent.
Pretty damn quiet here, I've done a small top yesterday on the basis that the share is back below 70p. I figure that the valuation is attractive at this level...cash is £7m or about 14.5p per share, so I compute a trailing ex cash PE on 2020 EPS of roughly 27x. EV EBITDA on trailing 2020 numbers of about 19.8x? the descoped Huntington disease trials will impact near term - does anyone have a view on H2 revenues/profits? in any case they should win enough new business to eventually offset that setback?
https://apple.news/AScjaq-aLQMasmd4AK8VXDg Times article Alzheimer’s drug, aducanumab, gives first new hope in 20 years The first new drug for Alzheimer’s disease in nearly 20 years won conditional approval today, offering fresh hope for British patients and millions of others worldwide. The US Food and Drugs Administration (FDA) said the company Biogen could market the drug, called aducanumab, in the United States, but that it would need to complete a further large clinical trial to confirm its benefit to patients. Regulators in Europe and the UK are not expected to make any ruling until the autumn but the US decision was hailed as promising by British campaigners. Professor Bart De Strooper, the director of the UK Dementia Research Institute, said: “With no effective therapies currently available to modify the progression of this devastating condition, this is a major milestone for the millions of people living with Alzheimer’s.” He warned however that “controversy and uncertainty” surrounding trials of the drug might limit the impact of the new treatment. Biogen’s decision to file for approval was a surprise after clinical trials involving over 3,000 people were stopped early in March 2019. An initial analysis showed the drugs were unlikely to make sufficient improvements to people’s memory and thinking. However, later that year the company said it had undertaken a new analysis with more data that became available after the trials stopped, focusing on people who had taken the drugs for longer. It said that analysis showed a high dose could slow the decline of cognitive skills and keep people able to carry out daily activities for longer, and requested approval on that basis. The drug is an antibody designed to target amyloid, a protein that builds up in the brain at an early stage of Alzheimer’s disease. While treatments work to reduce symptoms for a time, aducanumab aims to slow the underlying disease itself. The FDA said it was basing its unusual conditional approval on the ability of the drug, also known as Aduhelm, to clear the toxic proteins from the brain. For Biogen to continue marketing the drug, it will need to complete a trial to confirm removing the plaque offers cognitive benefits. Professor John Gallacher, director of Dementias Platform UK, said: “Although I suspect this was a close decision, the FDA obviously gave aducanumab the benefit of the doubt. “Apart from the chance for patient benefit, the scientific impact of this decision will be the real-world evidence it creates as the progress of people taking the drug is monitored.” He said it could also act as a catalyst for further drug development, suggesting other companies might “dust down” their own similar drugs for further work. Many experts are uneasy with the ruling. Dr Caleb Alexander, a drug safety and effectiveness expert at the Johns Hopkins Bloomberg school of public health, who was involved with an initial FDA decision to reject the application in November, told The New York Times that relying on a re-analysis of a trial was “like the Texas sharpshooter fallacy – the idea that the sharpshooter shoots up a barn and then goes and draws a bullseye around the cluster of holes that he likes”. Speaking before the decision, he warned approval would set a “remarkably dangerous precedent” for not only Alzheimer’s research but also broader regulation of prescription drugs. The American Geriatrics Society had urged the FDA not to approve the drug, citing concerns including “reliance on a single, incomplete trial as the basis for approval” and the fact that it was not free of side effects. There are about 850,000 people living with dementia in the UK. Dr Richard Oakley, head of research at Alzheimer’s Society, said: “It’s promising to see that aducanumab has been approved for use in people with early stage Alzheimer’s disease — the first drug to be approved in nearly 20 years by the US regulatory authorities. “We await the opinion of the European Medicines Agency and the outcome of any application made to the UK regulatory authorities, to give clarity to people with early Alzheimer’s disease in the UK.” He said that with the drug only likely to benefit a proportion of people in the early stages of the disease, “we must keep searching for drugs for all stages of Alzheimer’s disease and for other types of dementia”, calling on the government to honour a commitment to double dementia research funding.
IXICO ready to break 120p soon
IXI latest results meeting can be viewed soon on the IXICO website. The meeting was well managed and their performance in my view was excellent and gave an excellent account of their strategy covering future roadmap and technology directions highlighting new Products and Services being in high demand. Their Cash flow was positive and growing. The future is very Bright and a strong company set of accounts were positive and clearly explained. It was important to listen to the message and clear answers to the questions put forward. I am topping up as much as is available. The management team are outstanding and will steer IXICO to great heights.
I came away from the results meeting pretty underwhelmed. All the management team seemed really tired and would not look at the camera which created a rather odd disinterested impression . The answer to the Microsoft partnership question made it seem that it was more of enhanced support service than anything really value add. I am also a bit dismayed at the amount of time they spent talking about potential M&A and how it would be funded by a cap raise. Given they had just spent the last 45 mins talking about the organic growth runway, the move in to digital biomarkers and their less than 10% market share this focus on M&A surprised me a bit. I would ask the question why ? The fact they would even for a moment consider a non CNS M&A transaction needs some thought. I think the problem they face is that they do have a fair bit of competition and to break in to new trials areas they require validation but that validation, at least trials market wise, is hard to gain without being used in trials. Hence they are dominant in say Huntingtons but just a bit player in AD.
40 fathoms
RNS : IXICO plc Phase II Alzheimer's disease contract award Not sure how this operating model is going to work. £1m over 5 years - £200k per year. 125 sites - £1600 per site per year. Mmm a window cleaner makes more than that ! And once the client has had their drug development de-risked, fast-tracked and proven (or not) do Ixico just get dumped. Wait a minute ! Havent we been here before ? Oh yes, 23rd March Huntingtons disease.
Thread starter goes back seven years. Might be best to use other thread which has a price graph?
Is it possible the thread starter could add the price graphs to the header?
Another contract win for IXICO with their largest pharma client. Contract is worth US$0.5m. More significantly, the contract win reflects a further broadening of IXICO's neurological footprint into a new therapeutic area. Excellent news!
I don’t know halfpenny I have just read your posting history and now I am as confused as you clearly are.
IXI is it time to take profits after recent rally?
twitter @michae1mouse #IXI Strong trading update from IXICO this morning, and far less impact anticipated from ceased HD trial. Worst case was £7.7m now revised to £3.5m over 2 years. Order book up to £19m with cash at £7m. Growth in revs 8% in 1st half (£4.9m). Exciting growth story remains in tact.
Chat Pages: 24  23  22  21  20  19  18  17  16  15  14  13  Older
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210927 17:50:34